Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
Expert Interviews
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
Charles Gaulin, MBBS, discussed the future of lymphoma treatment, including the development of novel cellular therapies.
Viewpoints
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
The Blood Cancers Today Editorial Board offers their thoughts on the past year.
As we close 2023, it feels like we are all back, at full speed ahead, doing the work that draws us together and to our field.
Guillermo Garcia-Manero, MD, discusses contemporary issues regarding the management of LR-MDS.
This editorial outlines treatments for relapsed AML, T-Cell activation, and more.
The meeting had more than 2,500 registrants attending in person or online.
The practice of medicine, in many ways, can cycle like the seasons do.
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
The meeting will be held September 6-9, 2023, in Houston, Texas.
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
SOHO President Jennifer Brown, MD, PhD, reflects on the upcoming 11th SOHO Annual Meeting.
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
We went from survival of 10% to 90% and from full-fledged chemotherapy and transplant to a chemotherapy-free regimen.
Dr. Nastoupil reflects on the experiences that led her to study disparities in lymphoma and her hopes for the future.
World Blood Cancer Day is marked on May 28 each year.
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
The field of hematologic oncology is now contending with reconciling the proposed rival WHO and ICC systems.
Dr. Zeidan discusses a patient who shaped his career path, the pressing questions in MDS and AML, and more.
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.
April 21 is Acute Myeloid Leukemia World Awareness Day.
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Anastasia Tikhonova, PhD, talks about her research on the immune microenvironment in T-cell ALL.
Marina Konopleva, MD, PhD, tells us about the sessions that drew her eye at the 2023 AACR Annual Meeting.
The story of The Max Foundation begins with its namesake, Maximiliano “Max” M. Rivarola.
We will all experience burnout at some point, and we all need to seek more personalized ways to cope.
Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates and treatment considerations.
Dr. Wong hopes to see an expansion in the availability of new and novel treatments for myeloma.
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Nabhan discusses his new book, "Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice."
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
Mark Lawler, PhD, discusses insights from European Groundshot Report on survival trends and the future of cancer care.
Jennifer R. Brown, MD, PhD, and Anthony Mato, MD, MSCE, debate combinations versus sequencing approaches in CLL.
As 2023 begins, you'll want to listen to The HemOnc Pulse, a new podcast that brings you the latest in hematologic oncology.
Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, shares his hopes for CLL treatment and research in 2023.
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Sandy Wong, MD, of the University of California, San Francisco, shares what her hopes are in the New Year.
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
The past few years have been more than a challenge for those of us in health care, but we have learned many lessons.
Jerald Radich, MD; and Christopher S. Hourigan, MD, DPhil, FACP, FRCP; discuss minimal residual disease.
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Marina Konopleva, MD, PhD, discusses her new role at the Albert Einstein College of Medicine and highlights from her career ...
We are entering the great era of immunotherapy in multiple myeloma.
International Chronic Myeloid Leukemia (CML) Day takes place on September 22.
Guillermo Garcia-Manero, MD, gives his perspective.
September is Blood Cancer Awareness Month.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF).
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jeffrey Lancet, MD, of Moffitt Cancer Center, reflects on the mentorship that helped him through a career crossroads.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Decades in the making, information on measurable residual disease can greatly affect therapeutic decision making in ALL.
I welcome you to the first edition of Blood Cancers Today.
Farhad Ravandi, MD, and Jeffrey Lancet, MD, squared off on this clinical quandary.
Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.
The devil is in the detail.
Drs. Vikas Gupta and Lawrence Boise debate this issue.
The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients receiving standard of care.
Differentiation between MGUS and SMM is currently based on indirect measures and surrogate markers of disease burden.
MGUS and SMM are considered clinically silent precursor conditions to multiple myeloma.
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD ...
Communication, clarity, patient education, and support from the healthcare team can all contribute to adherence to therapy.
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Peter Voorhees, PhD ...
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
Shaji Kumar, MD, discusses B-cell maturation antigen as a target for myeloma and belantamab mafodotin.
Sarah Holstein, MD, PhD, talks about BCMA as a target of interest for multiple myeloma, as well as other emerging targets.
Nina Shah, MD, discusses immunotherapy agents in the pipeline for multiple myeloma.
Nina Shah, MD, discusses novel immunotherapy agents in development for multiple myeloma and what to know about them.
Shaji Kumar, MD, highlighted how the treatment paradigm may change in the coming years.
The ENDURANCE trial assessed carfilzomib versus bortezomib plus lenalidomide and dexamethasone for newly diagnosed MM.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Viewpoints
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
Advertisement
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
The Blood Cancers Today Editorial Board offers their thoughts on the past year.
As we close 2023, it feels like we are all back, at full speed ahead, doing the work that draws us together and to our field.
Guillermo Garcia-Manero, MD, discusses contemporary issues regarding the management of LR-MDS.
This editorial outlines treatments for relapsed AML, T-Cell activation, and more.
The meeting had more than 2,500 registrants attending in person or online.
The practice of medicine, in many ways, can cycle like the seasons do.
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
The meeting will be held September 6-9, 2023, in Houston, Texas.
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
SOHO President Jennifer Brown, MD, PhD, reflects on the upcoming 11th SOHO Annual Meeting.
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
We went from survival of 10% to 90% and from full-fledged chemotherapy and transplant to a chemotherapy-free regimen.
Dr. Nastoupil reflects on the experiences that led her to study disparities in lymphoma and her hopes for the future.
World Blood Cancer Day is marked on May 28 each year.
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
The field of hematologic oncology is now contending with reconciling the proposed rival WHO and ICC systems.
Dr. Zeidan discusses a patient who shaped his career path, the pressing questions in MDS and AML, and more.
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.
April 21 is Acute Myeloid Leukemia World Awareness Day.
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Anastasia Tikhonova, PhD, talks about her research on the immune microenvironment in T-cell ALL.
Marina Konopleva, MD, PhD, tells us about the sessions that drew her eye at the 2023 AACR Annual Meeting.
The story of The Max Foundation begins with its namesake, Maximiliano “Max” M. Rivarola.
We will all experience burnout at some point, and we all need to seek more personalized ways to cope.
Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates and treatment considerations.
Dr. Wong hopes to see an expansion in the availability of new and novel treatments for myeloma.
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Nabhan discusses his new book, "Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice."
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
Mark Lawler, PhD, discusses insights from European Groundshot Report on survival trends and the future of cancer care.
Jennifer R. Brown, MD, PhD, and Anthony Mato, MD, MSCE, debate combinations versus sequencing approaches in CLL.
As 2023 begins, you'll want to listen to The HemOnc Pulse, a new podcast that brings you the latest in hematologic oncology.
Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, shares his hopes for CLL treatment and research in 2023.
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Sandy Wong, MD, of the University of California, San Francisco, shares what her hopes are in the New Year.
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
The past few years have been more than a challenge for those of us in health care, but we have learned many lessons.
Jerald Radich, MD; and Christopher S. Hourigan, MD, DPhil, FACP, FRCP; discuss minimal residual disease.
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Marina Konopleva, MD, PhD, discusses her new role at the Albert Einstein College of Medicine and highlights from her career ...
We are entering the great era of immunotherapy in multiple myeloma.
International Chronic Myeloid Leukemia (CML) Day takes place on September 22.
Guillermo Garcia-Manero, MD, gives his perspective.
September is Blood Cancer Awareness Month.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF).
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jeffrey Lancet, MD, of Moffitt Cancer Center, reflects on the mentorship that helped him through a career crossroads.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Decades in the making, information on measurable residual disease can greatly affect therapeutic decision making in ALL.
I welcome you to the first edition of Blood Cancers Today.
Farhad Ravandi, MD, and Jeffrey Lancet, MD, squared off on this clinical quandary.
Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.
The devil is in the detail.
Drs. Vikas Gupta and Lawrence Boise debate this issue.
The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients receiving standard of care.
Differentiation between MGUS and SMM is currently based on indirect measures and surrogate markers of disease burden.
MGUS and SMM are considered clinically silent precursor conditions to multiple myeloma.
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD ...
Communication, clarity, patient education, and support from the healthcare team can all contribute to adherence to therapy.
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Peter Voorhees, PhD ...
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
Shaji Kumar, MD, discusses B-cell maturation antigen as a target for myeloma and belantamab mafodotin.
Sarah Holstein, MD, PhD, talks about BCMA as a target of interest for multiple myeloma, as well as other emerging targets.
Nina Shah, MD, discusses immunotherapy agents in the pipeline for multiple myeloma.
Nina Shah, MD, discusses novel immunotherapy agents in development for multiple myeloma and what to know about them.
Shaji Kumar, MD, highlighted how the treatment paradigm may change in the coming years.
The ENDURANCE trial assessed carfilzomib versus bortezomib plus lenalidomide and dexamethasone for newly diagnosed MM.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Expert Interviews
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
Charles Gaulin, MBBS, discussed the future of lymphoma treatment, including the development of novel cellular therapies.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.